Phathom Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PHAT | LXRX | VOR | VOGX | PTHS | BHVN | |
|---|---|---|---|---|---|---|
| Market cap | 461.74M | 658.53M | 1.24B | 293.09M | 39.91M | 2.30B |
| P/E (TTM) | — | — | 0.1 | — | — | — |
| Forward P/E | 5.9 | -7.8 | -5.7 | — | -1.9 | -8.2 |
| Price/book | -1.3 | 3.8 | -9.0 | -58.4 | -25.1 | -23.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −56.78% | +3.50% | −5.02% | +57.92% | −70.86% | +78.66% |
| Today | −1.05% | +1.37% | +1.31% | −3.90% | −5.84% | −2.37% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All PHAT news ›Aquestive Therapeutics GAAP EPS of -$0.18 misses by $0.06, revenue of $7.5M misses by $3.52M
Aquestive Therapeutics Q3 earnings missed on EPS and revenue as losses widened. - Aquestive Therapeutics press release (AQST): Q3 GAAP EPS of -$0.18 misses by $0.06. - Revenue of $7.5M (-41.5% Y/Y) misses by $3.52M.
Recent Analysts’ Ratings Changes for Phathom Pharmaceuticals (PHAT)
Posted by Tristan Rich on Nov 3rd, 2026 Several brokerages have updated their recommendations and price targets on shares of Phathom Pharmaceuticals (NASDAQ: PHAT) in the last few weeks: In the United States, Voquezna is approved for the…
Phathom Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation
2026-11-02. The following slide deck was published by Phathom Pharmaceuticals, Inc. The following slide deck was published by Phathom Pharmaceuticals, Inc. in conjunction with their 2026 Q3 earnings call. Q3: 2026-10-29 Earnings Summary
Phathom reiterates $310M-$325M 2026 revenue guidance while rolling out $0 co-pay via BlinkRx
Phathom Q3 2026 earnings: VOQUEZNA growth, positive cash flow, Access First strategy, and exclusivity risks. Earnings Call Insights: Phathom Pharmaceuticals (PHAT) Q3 2026 "Over the past 1.5 years, Phathom has significantly strengthened…
Patient intake platform Phreesia prepares to go public
The healthcare technology company will be trading in the New York Stock Exchange under the ticker symbol "PHR." Patient intake platform Phreesia announced this week that it has publicly filed a registration statement on Form S-1 with the…
Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting
Oct 27, 2026, 06:50 ET Based on the totality of data from the Phase II and Phase III programs, Vanda intends to discuss the results with the U.S. Food and Drug Administration (FDA) and is planning a supplemental New Drug Application (sNDA)…
Phathom Pharmaceuticals to Present New Data and Analyses for VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting
FLORHAM PARK, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced…
Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026
Additional Phathom-Sponsored Data at ACG 2026 Independent Research on Vonoprazan Presented at ACG 2026: Key areas of independent research presented at ACG 2026 include: Note: The independent research described in this press release…
Phathom Pharmaceuticals announces initiation of Phase 3 study of VOQUEZNA
Phathom Pharmaceuticals (PHAT) announced the initiation of patient screening in pHalcon-NERD-302, a registrational Phase 3 study evaluating an a... Phathom Pharmaceuticals announces initiation of Phase 3 study of VOQUEZNA Phathom…
More from 1 other outlet
Transcript : Phathom Pharmaceuticals, Inc., Q2 2026 Earnings Call, Jul 30, 2026
Presentation Operator MessageOperator Good day, ladies and gentlemen. Hello, and welcome to Phathom Pharmaceuticals' Second Quarter 2026 Earnings Results Call. [Operator Instructions] Please be... Transcript : Phathom Pharmaceuticals,…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com7
- markets.businessinsider.com6
- marketscreener.com5
- biospace.com1
- builtin.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 22 articles, not a forecast.